GZMB and cancer: We have developed mutated versions of these effector proteins to increase their potency, e.g. the granzyme B point mutant R201K is resistant to the natural granzyme B inhibitor serpin proteinase inhibitor 9 (PI-9), thus increasing its pro-apoptotic effect against target cancer cells [28, 30, 32].